Natural Compound

Pycnogenol

French Maritime Pine Bark Extract (Pinus pinaster ssp. atlantica)

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

100-200

watchEffect Window

2-4 weeks for circulatory and erectile benefits.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Pycnogenol is a standardized French maritime pine bark extract rich in procyanidins. It is used for vascular function, circulation symptoms, oxidative stress reduction, and skin elasticity support.

Trials support improved endothelial function and modest reductions in blood pressure, plus symptom improvement in chronic venous insufficiency. A 2025 meta-analysis also found small favorable shifts in fasting glucose, HbA1c, LDL cholesterol, and body weight, though heterogeneity remains substantial and several lipid and adiposity endpoints did not improve. Minority studies suggest benefits for erectile function in combination protocols, skin elasticity, and menstrual discomfort, but most of that literature is product-specific and often manufacturer-linked.

Stimulates endothelial nitric oxide synthase (eNOS) to increase nitric oxide, inducing vasodilation. Acts as a direct antioxidant and mildly inhibits alpha-glucosidase to improve blood glucose control.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Improves symptoms of chronic venous insufficiency and systemic blood flow
  • Highly effective for mild-to-moderate ED when combined with L-arginine (Prelox)

Secondary Outcomes

  • Modest reductions in fasting blood glucose in diabetic patients
  • Antioxidant activity and emerging cognitive/skin health benefits

Safety

Contraindications and Interactions

Contraindications

  • Active immunosuppressant therapy (possible immune-stimulating activity)
  • Autoimmune disease
  • Scheduled surgery within 2 weeks (antiplatelet effect)
  • Pregnancy or lactation

Side effects

  • GI discomfort (including stomach pain and nausea, usually mild/transient)
  • Headache (usually mild/transient)
  • Dizziness (usually mild/transient)
  • Drowsiness (usually mild/transient)

Interactions

  • Blood-thinning drugs (Theoretical/Unknown, e.g., anticoagulants/antiplatelets) - Potential additive antiplatelet effects. Monitor for bruising/bleeding.
  • Blood-pressure-lowering drugs (Possible/Minor, e.g., antihypertensives) - Potential additive blood pressure lowering. Monitor for dizziness/hypotension.
  • Blood-glucose-lowering drugs (Possible/Minor, e.g., insulin or oral hypoglycemics) - Potential additive glucose lowering. Monitor for hypoglycemia.
  • Blood-thinning supplements (Theoretical/Unknown) - Potential additive bleeding risk.
  • Blood-pressure-lowering supplements (Theoretical/Unknown) - Potential additive hypotension risk.
  • Blood-glucose-lowering supplements (Theoretical/Unknown) - Potential additive glucose-lowering risk.

Avoid if

  • Pregnancy or lactation
  • Autoimmune disease
  • Active immunosuppressant therapy
  • Scheduled surgery within 2 weeks

Evidence

Study-level References

pycnogenol-SRC-001Clinical Trial
Sourceopen_in_new

Stanislavov R, Nikolova V. "Treatment of erectile dysfunction with pycnogenol and L-arginine." J Sex Marital Ther. 2003.

Population: Men with organic erectile dysfunction

Key findings: After 3 months of treatment with the combination of L-arginine and Pycnogenol, 92.5% of the men experienced normal erections. Pycnogenol alone was not assessed in this specific cohort, proving the strong synergy between the two compounds.

Paper content

After 3 months of treatment with the combination of L-arginine and Pycnogenol, 92.5% of the men experienced normal erections. Pycnogenol alone was not assessed in this specific cohort, proving the strong synergy between the two compounds.

pycnogenol-SRC-002Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Mohammadi S, Fulop T, Khalil A, Ebrahimi S, Hasani M, Ziaei S, Farsi F, Mirtaheri E, Afsharianfar M, Heshmati J. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complement Med Ther. 2025;25(1):71. doi:10.1186/s12906-025-04819-9. PMID:39987124.

Population: Adults enrolled in randomized pine bark extract trials targeting cardiometabolic risk factors

Dose protocol: Meta-analysis of 27 RCTs using standardized pine bark extracts.

Key findings: Pooled evidence found modest reductions in systolic and diastolic blood pressure, fasting glucose, HbA1c, LDL cholesterol, and body weight, with no clear effect on triglycerides or HDL.

Notes: Useful for cardiometabolic framing, but product heterogeneity and short trial durations limit certainty.

Paper content

This open-access meta-analysis pooled 27 randomized trials with 1,685 participants and found modest improvements in systolic and diastolic blood pressure, fasting glucose, HbA1c, LDL cholesterol, and body weight with pine bark extract. It also showed no clear benefit for BMI, waist metrics, insulin, HDL cholesterol, triglycerides, or total cholesterol, which is important because the broader marketing claims often ignore those null outcomes. The paper included multiple branded and non-branded pine bark extracts, so it supports adjunct cardiometabolic framing for the class more than it proves that every generic pine bark product will match the better-studied Pycnogenol literature.

pycnogenol-SRC-003Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Bayer J, Petersen NK, Hess JV, Jockel-Schneider Y, Hogger P. Impact of Pycnogenol on Salivary and Serum Inflammatory Biomarkers During Non-Surgical Periodontal Therapy. Nutrients. 2025;17(9):1546. doi:10.3390/nu17091546. PMID:40362854.

Population: Adults with gingival inflammation undergoing professional mechanical plaque removal.

Dose protocol: Pycnogenol 200 mg/day for 3 months during non-surgical periodontal therapy in 91 adults.

Key findings: Reduced salivary MMP-8 and serum IL-6 versus placebo. Increased salivary polyphenol metabolites. Inverse correlation between metabolite M1 and bleeding on probing.

Notes: Provides direct human anti-inflammatory evidence in a controlled clinical setting.

Paper content

This double-blind placebo-controlled trial tested Pycnogenol 200 mg/day for 3 months alongside periodontal therapy in 91 adults with gingival inflammation. The Pycnogenol group showed significantly lower salivary MMP-8 and serum IL-6 than placebo, alongside increased polyphenol metabolites in saliva. An inverse correlation was observed between metabolite M1 and bleeding on probing. This provides direct human evidence for Pycnogenol's anti-inflammatory effects during an oral health intervention, supporting its systemic anti-inflammatory activity in a controlled clinical setting.

pycnogenol-SRC-004Systematic review of 39 randomized, double-blind, placebo-controlled trials.
Sourceopen_in_new

Weichmann F, Rohdewald P. Pycnogenol French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies. Front Nutr. 2024;11:1389374. doi:10.3389/fnut.2024.1389374. PMID:38757130.

Population: 2009 subjects across 39 RCTs spanning multiple health domains.

Dose protocol: Systematic overview of 39 randomized, double-blind, placebo-controlled trials covering 2009 subjects.

Key findings: Consistent cardiovascular and CVI benefits across multiple trial domains. Additional supportive signals for cognitive, joint, skin, and oral health.

Notes: Most comprehensive RDP overview of Pycnogenol to date. Authors include manufacturer-affiliated researchers.

Paper content

This 2024 systematic overview examined all 39 randomized, double-blind, placebo-controlled trials of Pycnogenol, covering 2009 subjects across multiple health domains. The review confirmed consistent cardiovascular and chronic venous insufficiency benefits, along with supportive evidence for cognitive, joint, skin, respiratory, and oral health outcomes. The antioxidative, anti-inflammatory, and endothelial function improvements provide a coherent mechanism across domains. This is a useful modern summary of the Pycnogenol RDP evidence landscape, though the authors include researchers affiliated with the manufacturer.

pycnogenol-SRC-005Randomized, double-blind, placebo-controlled clinical trial.
Sourceopen_in_new

Mello Netto BAS, Corassa JM, Barros FS, et al. Impact of Pycnogenol Use in the Treatment of Patients With Lipedema: A Randomized Controlled Trial. Cureus. 2025;17(11):e96589. doi:10.7759/cureus.96589. PMID:41393612.

Population: Women aged 18 to 40 years with a clinical diagnosis of lipedema.

Dose protocol: 50 mg for 60 days in women with lipedema

Key findings: Reduced lipedema symptom scores and improved body-composition metrics versus placebo over 60 days.

Notes: Interesting supportive women’s-health signal, but not a reason to reframe Pycnogenol as a generic fat-loss supplement.

Paper content

This 60-day double-blind placebo-controlled trial randomized 100 women with lipedema to Pycnogenol or placebo. Compared with placebo, the intervention group showed a progressive reduction in QuASiL symptom scores by 30 and 60 days and also had statistically significant reductions in body weight, BMI, and body fat percentage. The signal is interesting because lipedema overlaps with venous and inflammatory symptoms where Pycnogenol is mechanistically plausible, but the study was single-center, short, and had baseline weight imbalance between groups. It is best treated as supportive women’s-health evidence rather than a reason to market Pycnogenol as a weight-loss product.

Guides

Setup

Help